Cargando…

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women

BACKGROUND: Endometrial cancer is the second most frequent genital malignancy in women, which is showing a constant rise all over world. Endometrial hyperplasia is the precursor of endometrial cancer. Levonorgestrel intrauterine system is the first line management in patients with endometrial hyperp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinnekere Ravi, Ramya, Kalra, Jasvinder, Srinivasan, Radhika, Bagga, Rashmi, Jain, Vanita, Suri, Vanita, Sachdeva, Naresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286694/ https://www.ncbi.nlm.nih.gov/pubmed/33773565 http://dx.doi.org/10.31557/APJCP.2021.22.3.983

Ejemplares similares

Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia
por: Shen, Ye, et al.
Publicado: (2022)

Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study
por: O'Hara, Montana, et al.
Publicado: (2021)

Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
por: Girbash, Ehab F., et al.
Publicado: (2023)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

MicroRNAs as Predictors of Future Uterine Malignancy in Endometrial Hyperplasia without Atypia
por: Lin, Chiao-Yun, et al.
Publicado: (2022)

Post placental insertion of intrauterine contraceptive device
por: Suri, Vanita
Publicado: (2012)

The value of MRI in management of endometrial hyperplasia with atypia
por: Natarajan, Purushothaman, et al.
Publicado: (2020)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens
por: Ørbo, A, et al.
Publicado: (2015)

Prostatic Stromal Hyperplasia with Atypia
por: Hutchinson, Ryan C., et al.
Publicado: (2013)

Peripartum hysterectomy in a tertiary care hospital: Epidemiology and outcomes
por: Sharma, Bharti, et al.
Publicado: (2017)

Obstetric Teleconsultation by Using Mobile Phone Technology in COVID Pandemic
por: Sharma, Bharti, et al.
Publicado: (2023)

Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
por: Graul, Ashley, et al.
Publicado: (2018)

Prediction of Responsiveness to Clomiphene Citrate in Infertile Women with PCOS
por: Sachdeva, Garima, et al.
Publicado: (2019)

Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene
por: Sachdeva, Garima, et al.
Publicado: (2019)

Obese and Non-obese Polycystic Ovarian Syndrome: Comparison of Clinical, Metabolic, Hormonal Parameters, and their Differential Response to Clomiphene
por: Sachdeva, Garima, et al.
Publicado: (2019)

Comparison of Clinical, Metabolic, Hormonal, and Ultrasound Parameters among the Clomiphene Citrate-Resistant and Clomiphene Citrate-Sensitive Polycystic Ovary Syndrome Women
por: Sachdeva, Garima, et al.
Publicado: (2019)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
por: Chen, Xiaojun
Publicado: (2019)

Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience
por: Wang, Yang, et al.
Publicado: (2019)

The placental pathology in Coronavirus disease 2019 infected mothers and its impact on pregnancy outcome
por: Joshi, Bharti, et al.
Publicado: (2022)

Non-contraceptive applications of the levonorgestrel intrauterine system
por: Rodriguez, Maria Isabel, et al.
Publicado: (2010)

Role of the levonorgestrel intrauterine system in effective contraception
por: Attia, Abdelhamid M, et al.
Publicado: (2013)

Randomized controlled trial of cefazolin monotherapy versus cefazolin plus azithromycin single dose prophylaxis for cesarean deliveries: A developing country's perspective
por: Jyothi, Manjeera S., et al.
Publicado: (2019)

Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review
por: Peng, Hongfa, et al.
Publicado: (2022)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Levonorgestrel-Releasing Intrauterine System and Iron Overload Syndrome
por: Vieira da Motta, Marcia, et al.
Publicado: (2013)

The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids
por: Wrona, Wojciech, et al.
Publicado: (2017)

Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women
por: Joo, Jong-Kil, et al.
Publicado: (2021)

Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women
por: Dogiparthi, Anuradha, et al.
Publicado: (2010)

Rationalizing Treatment for Gynecological Cancers During the COVID-19 Pandemic: An Indian Experience
por: Srinivasa, G. Y., et al.
Publicado: (2020)

Weight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients
por: Isono-Taniguchi, Roze, et al.
Publicado: (2023)

Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy
por: Hui, Lee Shi, et al.
Publicado: (2021)

The Accuracy of Integrated [(18)F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Detection of Pelvic and Para-aortic Nodal Metastasis in Patients with High Risk Endometrial Cancer
por: Gholkar, Nikhil Shirish, et al.
Publicado: (2014)

Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system
por: Nikolopoulos, Manolis, et al.
Publicado: (2020)

Development of endometrial cancer after long-term usage of the levonorgestrel-releasing intrauterine system
por: Steshenko, Alexander, et al.
Publicado: (2021)

The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
por: Beatty, Megan N, et al.
Publicado: (2009)

Abnormal uterine bleeding in midlife: The role of levonorgestrel intrauterine system
por: Shawki, Osama, et al.
Publicado: (2013)

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases
por: Kim, Mi-La, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7fathuth61fo3aebk4b354js8r